Psychedelic Use and Behavioral Addictions

Journal of Psychoactive Drugs, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 14

Published: March 15, 2025

Recent clinical trials on classic psychedelics for depression and anxiety have raised questions about their potential to treat other psychiatric conditions. Evidence from pre-clinical research suggests may help with substance use disorders, ongoing registered trials. Behavioral addictions, sharing features also respond psychedelic treatment. This study examined self-reported symptoms of problem gambling, sexual addiction, compulsive buying, eating disorders in a community sample (N = 1107), alongside measures well-being (self-transcendence, personal growth, depression/anxiety, etc.), psychoactive drugs. Significant positive correlations emerged among behavioral addiction symptoms, inverse between addictions. Psychedelic users reported greater lower even after controlling demographics drug use. Principal components analysis showed that addictions formed single factor, which was combined into composite score. Multiple regression analyses revealed major stimulant, alcohol, nicotine vaping predicted higher scores, while uniquely scores. These findings suggest aid treating A controlled pilot or trial is warranted explore this therapeutic further.

Language: Английский

---

Pharmacological Monotherapy for Depressive Disorders: Current and Future, a Narrative Review

Medicina, Journal Year: 2025, Volume and Issue: 61(4), P. 558 - 558

Published: March 21, 2025

Objective: To narratively review currently available antidepressants and future potential as monotherapy for the treatment of depressive disorders. Methods: Selective serotonin reuptake inhibitors (SSRIs), norepinephrine (SNRIs), dopamine inhibitor (bupropion), tricyclic (TCAs), monoamine oxidase (MAOIs) were reviewed according to results from Sequenced Treatment Alternatives Relieve Depression (STAR*D) Study systematic reviews. For rest antidepressants, a PubMed/Medline search was conducted with priority drugs in development disorders, PubMed, Google, Clinicaltrials.gov databases used. Results: The STAR*D demonstrated that sertraline, venlafaxine, bupropion had similar efficacy patients major disorder (MDD) who failed citalopram. A network meta-analyses randomized, placebo-controlled trials found SSRIs, SNRIs, bupropion, TCAs, mirtazapine, agomelatine relative compared placebo, but different acceptability. Gepirone more failed/negative studies smaller effect size placebo other antidepressants. combination dextromethorphan ketamine infusion, intranasal esketamine faster onset action monoamine-based monotherapy. Brexanolone zuranolone are effective postpartum depression (PPD), MDD or adjunctive therapy very small. Psychedelics, glutamate receptor-related agents, kappa opioid receptor antagonists, orexin new anti-inflammatory biomarker-based antidepressant have been under investigation Psychedelics showed action, large size, long durability. Conclusions: Monoamine-based likely continue be mainstream disorder. NMDA antagonists neurosteroid will play bigger role improvement accessibility. may become game changer if phase III validate their safety

Language: Английский

---

The Emergence of Psilocybin in Psychiatry and Neuroscience

Pharmaceuticals, Journal Year: 2025, Volume and Issue: 18(4), P. 555 - 555

Published: April 9, 2025

Psilocybin, a naturally occurring psychedelic compound, has garnered renewed scientific interest for its potential in treating psychiatric and neurological disorders. This review systematically examines the latest research on psilocybin’s pharmacokinetics, pharmacodynamics, clinical efficacy, safety profile. Emerging evidence supports efficacy conditions such as major depressive disorder (MDD), treatment-resistant depression (TRD), anxiety, alcohol use disorders (AUD), cancer-related distress. Despite promising outcomes, significant barriers remain, including methodological constraints, regulatory hurdles, limited population diversity trials. Advances biosynthetic production optimized psychotherapeutic integration are necessary to ensure scalability accessibility. Future should focus long-term safety, dosing precision, neurobiological mechanisms refine therapeutic applications. provides critical foundation advancing evidence-based of psilocybin.

Language: Английский

---

Vortioxetine for depression in adults: A systematic review and dose–response meta‐analysis of randomized controlled trials

Psychiatry and Clinical Neurosciences, Journal Year: 2024, Volume and Issue: 78(9), P. 536 - 545

Published: July 3, 2024

Major depressive disorder (MDD) is a prevalent psychiatric condition and vortioxetine offers promising antidepressant effects due to its unique pharmacological profile. However, the dose-response relationships of for MDD not well established. We aimed conduct meta-analyses fill this gap.

Language: Английский

---

Comparison between Single-Dose and Two-Dose Psilocybin Administration in the Treatment of Major Depression: A Systematic Review and Meta-Analysis of Current Clinical Trials

Brain Sciences, Journal Year: 2024, Volume and Issue: 14(8), P. 829 - 829

Published: Aug. 18, 2024

Current pharmacological treatments for major depressive disorder (MDD) are often only partially effective, with many patients experiencing no significant benefit, leading to treatment-resistant depression (TRD). Psilocybin, a classical serotonergic psychedelic, has emerged as notable emerging treatment such disorders. The aim of this systematic review and meta-analysis is summarize discuss the most recent evidence about therapeutic effects single-dose two-dose psilocybin administration on severity symptoms, well compare efficacy these interventions among primary diagnosis MDD or TRD. Articles were collected from EBSCOhost PubMed following PRISMA guidelines, yielding 425 articles 138 duplicates. After screening 287 records, 12 studies met eligibility criteria included in review. A quantitative analysis indicates that highly effective reducing symptoms Both significantly reduced severity, sometimes more pronounced lasting effects. However, it unclear if was solely due dosage other factors. Future research should include standardized trials comparing dosing strategies better inform clinical practice.

Language: Английский

---

Qualitative Research on Psilocybin-Assisted Psychotherapy for the Treatment of Mental Health Disorders: A Scoping Review Protocol

Published: Oct. 7, 2024

IntroductionThere has been a surge in research into psilocybin-assisted psychotherapy over the past decade, with many studies indicating this may be an effective novel intervention for several mental health disorders. Researchers are increasingly incorporating qualitative analysis their recognition of rich, contextual information provides. This scoping review aims to identify existing on treatment disorders, analyse trends questions and methods, recognise opportunities future research. Methods AnalysisThe methodological guidelines set out JBI Manual Evidence Synthesis (Aromataris et al., 2024) will used conduct review. The include involving psychotherapy, administered controlled setting, any disorder. Microdosing excluded. PubMed, Scopus, PsycNET, reference lists included searched. Two reviewers screen papers inclusion. Data extracted table findings presented narrative form. Relevant identified, methods analysed, discussed.Ethics DisseminationEthics approval is not required. Findings submitted publication peer-reviewed journal. Key Words or PhrasesAnxiety, depression, psilocybin, psychedelic, qualitative.

Language: Английский

---

Psychedelic Research for Alcohol Use Disorder with Comorbid Major Depressive Disorder: An Unmet Need

Current Psychiatry Reports, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 29, 2024

Language: Английский

---